

ASX Announcement | 23 July 2024 AdAlta Limited (ASX:1AD)

Extraordinary General Meeting approves all resolutions

AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body® platform advises that all resolutions proposed at its Extraordinary General Meeting have been carried with support of more than 98% of shares voted. The meeting was held today at 11:00am AEDT to consider resolutions to ratify past issuance, and to approve certain future issuance, of shares related to previously announced (29 April 2024) institutional investment facilities and other activities.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that details of the resolutions and the votes received in respect of each resolution are set out in the attached summary.

This ASX announcement has been authorised for release by Tim Oldham CEO & Managing Director of AdAlta Limited (ASX:1AD).

For further information, please contact:

AdAlta Limited (ASX:1AD)

Tim Oldham
CEO & Managing Director
P: +61 3 9479 5159
E: t.oldham@adalta.com.au

Media & Investor Enquiries

The Capital Network
Julia Maguire
P: +61 2 8999 3699
E: julia@thecapitalnetwork.com.au

About AdAlta Limited

AdAlta Limited (ASX:1AD) is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body® technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody-enabled protein and cell therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body® technology creates a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta's strategy is to maximise the products developed using its next generation i-body® platform by discovering and developing selected i-body®-enabled product candidates useful in fibrosis, inflammation and cancer; and partnering with other biopharmaceutical companies to develop these and other product candidates in a range of indications and product formats

AdAlta's current lead i-body® enabled candidate is AD-214, which is taking a wholly new approach to treat lung fibrosis (IPF) and other fibrotic diseases. In accord with its business model, AdAlta is creating a private, unlisted subsidiary called AdSolis to advance AD-214 into Phase II clinical trials through licensing and/or third-party investment.

AdAlta believes that the i-body® technology is ideally suited for use in the creation of advanced cellular immunotherapies for cancer and that this field represents an opportunity to expand its clinical stage pipeline. It has entered a Memorandum of Understanding with SYNthesis BioVentures to investigate the formation of a jointly owned entity, to be called AdCella, that, once established, will provide innovative cellular immunotherapies originating in Asia with a pathway to western regulated markets via Australian clinical trials and further enhancement with AdAlta's i-body® technology.

The Company is also entering collaborative discovery partnerships to advance the development of its i-body® platform. It has a collaboration with Carina Biotech to codevelop precision engineered, i-body® enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development.

For more information



Join our [InvestorHub](#)



Follow us on [Twitter](#)



Follow us on [LinkedIn](#)

To learn more about AdAlta please click here: www.adalta.com.au

Disclosure of Proxy Votes

AdAlta Limited

Extraordinary General Meeting
Tuesday, 23 July 2024



AUTOMIC
Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Ratification of prior issue of Shares to New Life Sciences Capital, LLC	P	297,141,184	294,487,521 99.11%	2,419,727 0.81%	890,369	233,936 0.08%	295,489,363 99.19%	2,419,727 0.81%	890,369	Passed
2 Ratification of grant of the First NLSC Investment Right to New Life Sciences Capital, LLC	P	297,141,184	294,487,521 99.11%	2,419,727 0.81%	890,369	233,936 0.08%	295,489,363 99.19%	2,419,727 0.81%	890,369	Passed
3 Ratification of prior issue of Shares to Skiptan Pty Ltd as trustee for the P&M Meurs Family Trust	P	231,098,218	228,402,857 98.83%	2,461,425 1.07%	372,500	233,936 0.10%	229,404,699 98.94%	2,461,425 1.06%	372,500	Passed
4 Ratification of grant of First Meurs Investment Right to Skiptan Pty Ltd as trustee for the P&M Meurs Family Trust	P	231,098,218	228,402,857 98.83%	2,461,425 1.07%	372,500	233,936 0.10%	229,404,699 98.94%	2,461,425 1.06%	372,500	Passed
5 Approval of grant of Second Meurs Investment Right to Skiptan Pty Ltd as trustee for the P&M Meurs Family Trust	P	231,098,218	228,402,857 98.83%	2,461,425 1.07%	372,500	233,936 0.10%	229,404,699 98.94%	2,461,425 1.06%	372,500	Passed
6 Ratification of prior issue of Shares to nominee of Grannus Securities	P	297,659,053	294,963,692 99.09%	2,461,425 0.83%	372,500	233,936 0.08%	295,965,534 99.18%	2,461,425 0.82%	372,500	Passed

